Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rapid VPRIV Infusion in Treatment-Naive Gaucher Disease
NCT03702361Phase 4Completed
- Sponsor
- Shaare Zedek Medical Center
- Start
- Sep 2018
- Primary completion
- Sep 2019
- Modality
- Replacement Enzymes
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of velaglucerase alfa in Gaucher disease type 1 (GD1), sponsored by Shaare Zedek Medical Center. Primary endpoint: Percent change from baseline in spleen volume measured by MRI at 12 months. Started Sep 2018; status: completed.
02
Drugs
velaglucerase alfa
03
Conditions
Gaucher disease type 1 (GD1)
Beyond the preview
Go deeper on NCT03702361.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03702361.